At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 63 enrolled
Drug / intervention
64Cu-DOTATATEdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-dose, Single Arm, Single-center Clinical Trial of 64Cu(Copper)-DOTATATE (NETMedix™) PET-CT Scan for Imaging Patients With Known or Suspected Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
In Brief
A Phase 3 clinical trial evaluating 64Cu-DOTATATE for Neuroendocrine Tumors. Completed, enrolled 63 participants across 1 site.
Detailed Summary
This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartAug 2018
First PostedSep 2018
Primary CompletionMar 2019
Study CompletionAug 2019
TodayJul 2026
First PostedSep 17, 2018
Enrollment StartAug 23, 2018
Primary CompletionMar 23, 2019
Study CompletionAug 7, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.8 years ago
Interventions
64Cu-DOTATATEdrug
Detection of somatostatin positive lesions in NET